Meeting News Coverage

Global comparative trials of Avastin and Lucentis continue to teach lessons

KOLOA, Hawaii – The list of clinical trials comparing Avastin and Lucentis is getting longer, adding weight to the suggestion that there is no significant difference between the drugs with regard to systemic serious adverse events, a presenter said here.

Worlwide, results of six trials have been published: CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS.

“Through 2 years, there was no difference between drugs in rates of death, myocardial infarction or stroke events,” CATT study chair and Chairmanof the Cole Eye Institute, Daniel F. Martin, MD, said at Retina 2014. “This has now been shown in every trial.”

Daniel F. Martin

Only in the CATT study did results find more systemic serious adverse events in patients treated with Avastin (bevacizumab, Genentech) than with Lucentis (ranibizumab, Genentech), but that result has not been replicated in any other study, Martin said.

Another safety issue is that of supply.

“It’s a fair concern,” Martin said. “But, millions of Avastin injections have been given and the number of complications related to supply is extraordinarily low. …Increased FDA oversight of compounding pharmacies should reduce this risk even further.” –by Patricia Nale

Disclosure: Martin has no relevant financial interests.

KOLOA, Hawaii – The list of clinical trials comparing Avastin and Lucentis is getting longer, adding weight to the suggestion that there is no significant difference between the drugs with regard to systemic serious adverse events, a presenter said here.

Worlwide, results of six trials have been published: CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS.

“Through 2 years, there was no difference between drugs in rates of death, myocardial infarction or stroke events,” CATT study chair and Chairmanof the Cole Eye Institute, Daniel F. Martin, MD, said at Retina 2014. “This has now been shown in every trial.”

Daniel F. Martin

Only in the CATT study did results find more systemic serious adverse events in patients treated with Avastin (bevacizumab, Genentech) than with Lucentis (ranibizumab, Genentech), but that result has not been replicated in any other study, Martin said.

Another safety issue is that of supply.

“It’s a fair concern,” Martin said. “But, millions of Avastin injections have been given and the number of complications related to supply is extraordinarily low. …Increased FDA oversight of compounding pharmacies should reduce this risk even further.” –by Patricia Nale

Disclosure: Martin has no relevant financial interests.

    See more from Hawaiian Eye/Retina Meeting